UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Psychosomatik - neurobiologisch fundiert und evidenzbasiert: Ein Lehr- und Handbuch

2nd ed., 2024

Volltextzugriff (PDF)

Psychosomatik - neurobiologisch fundiert und evidenzbasiert: Ein Lehr- und Handbuch

1st ed., 2020

Volltextzugriff (PDF)

Enhancing student understanding of rheumatic disease pathologies through augmented reality: findings from a multicentre trial

Rheumatology (Oxford, England), 2024-07, Vol.63 (7), p.1949-1956

2024

Volltextzugriff (PDF)

Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function

Blood, 2007-09, Vol.110 (5), p.1550-1558

2007

Volltextzugriff (PDF)

Outcomes of a Delirium Prevention Program in Older Persons After Elective Surgery: A Stepped-Wedge Cluster Randomized Clinical Trial

JAMA surgery, 2022-02, Vol.157 (2), p.e216370

2022

Volltextzugriff (PDF)

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

Leukemia, 2023-03, Vol.37 (3), p.650-658

2023

Volltextzugriff (PDF)

The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma

Annals of hematology, 2020-08, Vol.99 (8), p.1709-1725

2020

Volltextzugriff (PDF)

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Journal of viral hepatitis, 2019-02, Vol.26 (2), p.224-230

2019

Volltextzugriff (PDF)

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.287-288

2022

Volltextzugriff (PDF)

Psychosomatik - Neurobiologisch Fundiert Und Evidenzbasiert

2020

Volltextzugriff (PDF)

Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8521-8521

2020

Volltextzugriff (PDF)

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

Blood, 2018-11, Vol.132 (Supplement 1), p.1979-1979

2018

Volltextzugriff (PDF)

Forecast the grid oriented battery operation to enable a multi-use approach and discussion of the regulatory framework

CIRED - Open Access Proceedings Journal, 2017, Vol.2017 (1), p.2760-2763

2017

Volltextzugriff (PDF)

Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.3969-3969

2014

Volltextzugriff (PDF)

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Blood, 2012-11, Vol.120 (21), p.2012-2012

2012

Volltextzugriff (PDF)

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Blood, 2010-11, Vol.116 (21), p.1945-1945

2010

Volltextzugriff (PDF)

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy

Blood, 2011-11, Vol.118 (21), p.3967-3967

2011

Volltextzugriff (PDF)

Diagnostik und Therapie von Verletzungen der Halswirbelsäule im Kindesalter: Empfehlungen der AG Wirbelsäulentrauma im Kindesalter

Der Unfallchirurg, 2020-04, Vol.123 (4), p.252-268

2020

Volltextzugriff (PDF)

Diagnostik und Therapie von Verletzungen der Halswirbelsäule im Kindesalter

Der Unfallchirurg, 2020-01, Vol.123 (4), p.252-268

2020

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(23)
Deutsch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(6)
Hematology
(4)
Patients
(4)
Infectious Diseases
(3)
Medicine
(3)
Multiple Myeloma
(3)
Oncology
(3)
Virology
(3)
Aged
(2)
Bio-Psycho-Soziales Krankheitsmodell
(2)
Biopsy
(2)
Chronic Infection
(2)
Clinical Trials
(2)
Emergency Medicine
(2)
Female
(2)
Fibrosis
(2)
Gastroenterology & Hepatology
(2)
Hepatitis C
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Psychosomatik - neurobiologisch fundiert und evidenzbasiert: Ein Lehr- und Handbuch

Psychosomatik - neurobiologisch fundiert und evidenzbasiert: Ein Lehr- und Handbuch

Enhancing student understanding of rheumatic disease pathologies through augmented reality: findings from a multicentre trial

Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function

Outcomes of a Delirium Prevention Program in Older Persons After Elective Surgery: A Stepped-Wedge Cluster Randomized Clinical Trial

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Psychosomatik - Neurobiologisch Fundiert Und Evidenzbasiert

Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

Forecast the grid oriented battery operation to enable a multi-use approach and discussion of the regulatory framework

Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy

Diagnostik und Therapie von Verletzungen der Halswirbelsäule im Kindesalter: Empfehlungen der AG Wirbelsäulentrauma im Kindesalter

Diagnostik und Therapie von Verletzungen der Halswirbelsäule im Kindesalter

Suchergebnisse filtern